- Home
- GNFT vs CRGX Comparison
GNFT vs CRGX Comparison
Compare GNFT & CRGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNFT
- CRGX
- Stock Information
- Founded
- GNFT 1999
- CRGX 2021
- Country
- GNFT France
- CRGX United States
- Employees
- GNFT N/A
- CRGX N/A
- Industry
- GNFT Biotechnology: Biological Products (No Diagnostic Substances)
- CRGX
- Sector
- GNFT Health Care
- CRGX
- Exchange
- GNFT Nasdaq
- CRGX Nasdaq
- Market Cap
- GNFT N/A
- CRGX 180.4M
- IPO Year
- GNFT 2019
- CRGX 2023
- Fundamental
- Price
- GNFT $3.32
- CRGX $4.07
- Analyst Decision
- GNFT Strong Buy
- CRGX Hold
- Analyst Count
- GNFT 1
- CRGX 7
- Target Price
- GNFT $13.00
- CRGX $4.67
- AVG Volume (30 Days)
- GNFT 9.0K
- CRGX 773.9K
- Earning Date
- GNFT 04-24-2025
- CRGX 03-12-2025
- Dividend Yield
- GNFT N/A
- CRGX N/A
- EPS Growth
- GNFT N/A
- CRGX N/A
- EPS
- GNFT 0.47
- CRGX N/A
- Revenue
- GNFT $86,225,222.00
- CRGX N/A
- Revenue This Year
- GNFT $145.20
- CRGX $119.08
- Revenue Next Year
- GNFT N/A
- CRGX N/A
- P/E Ratio
- GNFT $7.66
- CRGX N/A
- Revenue Growth
- GNFT 175.45
- CRGX N/A
- 52 Week Low
- GNFT $3.11
- CRGX $3.00
- 52 Week High
- GNFT $6.42
- CRGX $25.45
- Technical
- Relative Strength Index (RSI)
- GNFT 45.10
- CRGX 40.37
- Support Level
- GNFT $3.35
- CRGX $3.98
- Resistance Level
- GNFT $3.68
- CRGX $4.25
- Average True Range (ATR)
- GNFT 0.08
- CRGX 0.22
- MACD
- GNFT 0.01
- CRGX 0.16
- Stochastic Oscillator
- GNFT 37.50
- CRGX 36.84
About CRGX CARGO Therapeutics Inc.
Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.